| Publications | PubMed=1283316; DOI=10.1002/gcc.2870050403
Aman P., Ron D., Mandahl N., Fioretos T., Heim S., Arheden K., Willen H., Rydholm A., Mitelman F.
Rearrangement of the transcription factor gene CHOP in myxoid liposarcomas with t(12;16)(q13;p11).
Genes Chromosomes Cancer 5:278-285(1992) PubMed=16651630; DOI=10.2353/ajpath.2006.050872; PMCID=PMC1606602
Engstrom K., Willen H., Kabjorn-Gustafsson C., Andersson C., Olsson M., Goransson M., Thelin-Jarnum S., Olofsson A., Warnhammar E., Aman P.
The myxoid/round cell liposarcoma fusion oncogene FUS-DDIT3 and the normal DDIT3 induce a liposarcoma phenotype in transfected human fibrosarcoma cells.
Am. J. Pathol. 168:1642-1653(2006) PubMed=20515481; DOI=10.1186/1471-2407-10-249; PMCID=PMC2889895
Andersson M.K., Goransson M., Olofsson A., Andersson C., Aman P.
Nuclear expression of FLT1 and its ligand PGF in FUS-DDIT3 carrying myxoid liposarcomas suggests the existence of an intracrine signaling loop.
BMC Cancer 10:249.1-249.10(2010) PubMed=24726063; DOI=10.1186/1756-9966-33-33; PMCID=PMC4022359
Koelsche C., Renner M., Hartmann W., Brandt R., Lehner B., Waldburger N., Alldinger I., Schmitt T., Egerer G., Penzel R., Wardelmann E., Schirmacher P., von Deimling A., Mechtersheimer G.
TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities.
J. Exp. Clin. Cancer Res. 33:33.1-33.8(2014) PubMed=25393000; DOI=10.1371/journal.pone.0113110; PMCID=PMC4231113
Stahlberg A., Kabjorn-Gustafsson C., Engtrom K., Thomsen C., Dolatabadi S., Jonasson E., Li C.-Y., Ruff D., Chen S.-M., Aman P.
Normal and functional TP53 in genetically stable myxoid/round cell liposarcoma.
PLoS ONE 9:E113110-E113110(2014) PubMed=26643872; DOI=10.18632/oncotarget.6464; PMCID=PMC4767443
Kanojia D., Nagata Y., Garg M., Lee D.H., Sato A., Yoshida K., Sato Y., Sanada M., Mayakonda A., Bartenhagen C., Klein H.-U., Doan N.B., Said J.W., Mohith S., Gunasekar S., Shiraishi Y., Chiba K., Tanaka H., Miyano S., Myklebost O., Yang H.H., Dugas M., Meza-Zepeda L.A., Silberman A.W., Forscher C., Tyner J.W., Ogawa S., Koeffler H.P.
Genomic landscape of liposarcoma.
Oncotarget 6:42429-42444(2015) PubMed=27270875; DOI=10.1038/labinvest.2016.64; PMCID=PMC4965313
de Graaff M.A., Yu J.S.E., Beird H.C., Ingram D.R., Nguyen T., Liu J.J.-H., Bolshakov S.V., Szuhai K., Aman P., Torres K.E., Lev D.C., Nielsen T.O., Bovee J.V.M.G., Lazar A.J.F., Somaiah N.
Establishment and characterization of a new human myxoid liposarcoma cell line (DL-221) with the FUS-DDIT3 translocation.
Lab. Invest. 96:885-894(2016) PubMed=30962207; DOI=10.15252/embr.201845766; PMCID=PMC6500973
Linden M., Thomsen C., Grundevik P., Jonasson E., Andersson D., Runnberg R., Dolatabadi S., Vannas C., Santamaria M.L., Fagman H., Stahlberg A., Aman P.
FET family fusion oncoproteins target the SWI/SNF chromatin remodeling complex.
EMBO Rep. 20:e45766.1-e45766.15(2019) |
|---|
